Radloff 1996.

Methods	Randomized controlled trial Length of follow up: 28 d Generation of allocation sequence: participants given a sequential study number, which was randomly assigned to treatment option Allocation concealment: unclear Blinding: none Inclusion of all randomized participants in the final analysis: 126 analysed/142 randomized (89%)
Participants	Number enrolled: 142 Age range: 15 to 65 years Gender: male and female (mainly male) Inclusion criteria: age 15 to 65 years; presence of acute uncomplicated falciparum malaria; parasitaemia between 200 and 100,000 parasites/µL; weight 40 kg and above; urine test negative for chloroquine or sulphonamides Exclusion criteria: severe malaria; presence of mixed infections with other Plasmodium species; presence of concomitant disease (intercurrent febrile infections); 2‐week history of antimalarial administration; pregnancy; breastfeeding mother
Interventions	1. Atovaquone plus proguanil (1000 mg atovaquone and 400 mg proguanil daily over 3 d) 2. Amodiaquine (1500 mg over 3 d: 600 mg on admission, 600 mg 24 h later, and 300 mg after a further 24 h)
Outcomes	1. 28‐d cure rate 2. Parasite clearance time 3. Fever clearance time
Notes	Location: Gabon Drug resistance: high for chloroquine